CD20-Directed Serotherapy in Patients With Multiple Myeloma: Biologic Considerations and Therapeutic Applications
- 1 January 2002
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 25 (1) , 72-81
- https://doi.org/10.1097/00002371-200201000-00008
Abstract
Clonotypic B cells circulating in patients with multiple myeloma (MM) express CD20, and it has been suggested that these cells may be clonogenic. Furthermore, 20% of patients with MM express CD20 on their bone marrow plasma cells (BMPCs). Therefore, the authors began a phase II clinical study to determine the activity of the anti-CD20 monoclonal antibody rituximab in MM patients. Nineteen previously treated MM patients received 375 mg/m 2 rituximab per week for 4 weeks. Three months after initiation of treatment, patients were assessed for response and received a second course of therapy if their disease was stable (SD) or they achieved a partial response (PR). Six of 19 (32%) patients had either a PR (n = 1) or SD (n = 5), with a median time to treatment failure of 5.5 months (mean, 10.3 months; range, 3–27+ months). All six patients who had a PR or SD had CD20 + BMPC. Overall, rituximab therapy was well tolerated. Because most patients with MM poorly express CD20 on their BMPCs, the authors evaluated agents for their ability to induce CD20 expression and thereby facilitate rituximab binding on MM cells. These studies show that interferon-gamma (IFN-γ) induced CD20 expression on MM BMPCs, MM B cells, and healthy donor BMPCs. In contrast, CD20 expression on chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma, healthy donor B cells, and progenitor cells was unaffected by IFN-γ. Rituximab binding to the BMPCs of MM patients was also increased after culture with pharmacologically attainable levels of IFN-γ (1–100 U/mL). In conclusion, these studies suggest that MM patients with CD20 + BMPCs may benefit from rituximab therapy. Furthermore, IFN-γ induces CD20 expression on MM BMPCs and B cells and facilitates rituximab binding to MM BMPCs, providing the rationale for clinical trials to examine its use with CD20-directed serotherapies in MM.Keywords
This publication has 55 references indexed in Scilit:
- High numbers of clonal CD19+ cells in the peripheral blood of a patient with multiple myelomaBritish Journal of Haematology, 1999
- Interferon Induces Up-regulation of Spi-1/PU.1 in Human Leukemia K562 CellsBiochemical and Biophysical Research Communications, 1997
- Upregulation of MHC class II antigen on dendritic cells from hepatitis B virus transgenic mice by interferon‐γ: abrogation of immune response defect to a T‐cell‐dependent antigenImmunology, 1996
- Major Histocompatibility Complex Class I and Class II Expression in Renal Cell Carcinoma and Modulation by Interferon GammaJournal of Urology, 1996
- Requirement of Transcription Factor PU.1 in the Development of Multiple Hematopoietic LineagesScience, 1994
- The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell.The Journal of Experimental Medicine, 1993
- Interferon‐γ induces cell surface expression for both types of tumor necrosis factor receptorsFEBS Letters, 1992
- Assessment of Tumour-infiltrating Lymphocytes, Regional Lymph Node Lymphocytes and Peripheral Blood Lymphocytes and their Reaction to Interferon-gamma in Patients with Renal CarcinomaBritish Journal of Urology, 1991
- Recombinant interferon- γ inhibits the growth of IL-6-dependent human multiple myeloma cell lines in vitroEuropean Journal of Haematology, 1991
- Interferon exerts a cytotoxic effect on primary human myeloma cellsEuropean Journal of Cancer and Clinical Oncology, 1988